31Mar 2022
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency

Intravenous ferric carboxymaltose (FCM) has improved overall quality of life in iron-deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR-HF and CONFIRM-HF pooled analysis explored the likelihood of individual improvement or deterioration in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains with FCM versus placebo and evaluated the stability of this response over time. Treatment of iron-deficient HFrEF patients with intravenous FCM conveyed clinically relevant improvements in health status at an individual-patient level; benefits were sustained over time in most patients.

  • #cardiology

Like

Save

Share